Skip to main content
. 2022 Jun 17;11(12):1950. doi: 10.3390/cells11121950

Figure 4.

Figure 4

The phrase “anti-VEGF” encompasses a variety of distinct compounds that inhibit angiogenesis. The four most studied structural compounds include aptamers (i.e., pegaptanib), antibodies to VEGF (i.e., bevacizumab), antibody fragments against VEGF (i.e., ranibizumab), fusion proteins (i.e., aflibercept), and heteroantibodies (i.e., Faricimab) (created with BioRender).